• CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells (T cells) that are genetically altered in a lab to enable them to locate in destroying cancer cells more effectively.
• The first successful clinical trial was published almost a decade ago, and the therapy in India was first performed in 2021.
• ImmunoACT has been granted approval by the Indian drug regulator Central Drugs Standard Control Organization (CDSCO) for its CAR-T cell therapy NexCAR19.
Imagine a disease that strikes fear into the hearts of people worldwide. You guessed it - cancer. It's a condition that has driven individuals to travel across oceans and spend fortunes pursuing a cure.
Brace yourself for Immune ACT, a groundbreaking treatment that promises to conquer r/r B-cell lymphomas and leukemia. The days of despair and uncertainty may soon be behind us as hope shines brightly on the horizon.
Big success for the nation
ImmunoACT, supported by IITB and Laurus Labs, has received approval from the Central Drugs Standard Control Organization (CDSCO) for India's first CAR-T cell therapy, NexCAR19. This therapy is used to treat r/r B-cell lymphomas and leukemia.
Immunoadoptive Cell Therapy Pvt. Ltd. got approval to market India's first humanized CD19-targeted CAR T cell therapy product for r/r B-cell lymphomas and leukemia.
NexCAR19 is a CAR-T cell therapy that targets CD19 and has been developed in India. It is the country's first product and represents a significant advancement in cell and gene therapies. It results from a ten-year collaboration between IIT-Bombay and Tata Memorial Centre.
Warriors who made it happen
Dr. Atharva Karulkar, Dr. Alka Dwivedi, Dr. Rahul Purwar, and their team at IIT Bombay designed and developed NexCAR19. The manufacturing process was carried out at ImmunoACT under cGMP guidelines. Clinical investigations and translational studies were led by Dr. Hasmukh Jain, Dr. Gaurav Narula, and their teams at TMH.
Kudos to the team of experts; this treatment brings fresh optimism and a glimmer of hope to patients fighting these destructive illnesses.
Edited by Shruti Thapa
